

Frederick L Locke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1947000/publications.pdf>

Version: 2024-02-01

116
papers

15,023
citations

126858

33
h-index

40954

93
g-index

121
all docs

121
docs citations

121
times ranked

10066
citing authors

#	ARTICLE	IF	CITATIONS
1	Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 555-567.	0.8	82
2	Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. <i>Blood</i> , 2022, 139, 1330-1339.	0.6	52
3	Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. <i>Blood Advances</i> , 2022, 6, 486-494.	2.5	25
4	A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. <i>Blood Advances</i> , 2022, 6, 259-269.	2.5	5
5	Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy: A Qualitative Study. <i>Oncology and Therapy</i> , 2022, 10, 123-141.	1.0	8
6	Solid Tumor TIL Therapy Is Infiltrating Multiple Centers With Lympho-â€œsightsâ€™ Set on Becoming Standard of Care. , 2022, 19, .		0
7	Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 640-654.	13.9	586
8	Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 305.e1-305.e9.	0.6	14
9	Transverse myelitis after anti-â€œCD19 directed CAR T cell therapy for relapsed large B cell lymphoma. <i>EJHaem</i> , 2022, 3, 223-227.	0.4	0
10	Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US. <i>Journal of Medical Economics</i> , 2022, 25, 541-551.	1.0	6
11	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. <i>Blood Cancer Discovery</i> , 2022, 3, 385-393.	2.6	29
12	Change in Patientsâ€™ Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 401.e1-401.e7.	0.6	10
13	The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. , 2022, 10, e004475.		50
14	Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 753-759.	0.2	6
15	Longitudinal Collection of Patient-Reported Outcomes and Activity Data during CAR-T Therapy: Feasibility, Acceptability, and Data Visualization. <i>Cancers</i> , 2022, 14, 2742.	1.7	6
16	Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 487.e1-487.e7.	0.6	4
17	Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 581.e1-581.e8.	0.6	61
18	Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL. <i>Blood Advances</i> , 2022, 6, 3970-3973.	2.5	6

#	ARTICLE	IF	CITATIONS
19	Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel. <i>Blood</i> , 2021, 137, 1832-1835.	0.6	48
20	Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 978-986.	1.7	141
21	Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. <i>Journal of Medical Economics</i> , 2021, 24, 458-468.	1.0	23
22	Antibodies Against Vaccine-preventable Infections After CD19 or BCMA CAR T-cell Therapy. , 2021, 18, .		0
23	IFN Signaling and Myeloid Cells in the Setting of CAR T: A Central Role for the Induction of Endogenous Anti-tumor Immunity. , 2021, 18, .		0
24	Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel. <i>Cancer Medicine</i> , 2021, 10, 1936-1943.	1.3	13
25	The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2021, 288, 20210229.	1.2	22
26	Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 242.e1-242.e6.	0.6	5
27	Quality of life in caregivers of patients receiving chimeric antigen receptor T-cell therapy. <i>Psycho-Oncology</i> , 2021, 30, 1294-1301.	1.0	6
28	CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. <i>Blood</i> , 2021, 138, 1081-1085.	0.6	84
29	Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. <i>Blood</i> , 2021, 137, 2621-2633.	0.6	137
30	CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. <i>Blood</i> , 2021, 138, 2499-2513.	0.6	160
31	Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1145-1154.	0.4	29
32	Objective and subjective physical function in allogeneic hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2021, 56, 2897-2903.	1.3	10
33	Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 885-907.	0.6	12
34	Seeing the light: CAR T cell targeting of lambda-restricted B cell lymphomas. <i>Clinical Cancer Research</i> , 2021, 27, clincanres.1450.2021.	3.2	0
35	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2911-2921.	1.3	21
36	Efficacy and safety of CD19-directed CAR cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. <i>American Journal of Hematology</i> , 2021, 96, 1295-1312.	2.0	107

#	ARTICLE	IF	CITATIONS
37	ABCL-289: Matching-Adjusted Indirect Comparison (MAIC) of Axicabtagene Ciloleucel (Axi-Cel) and Lisocabtagene Maraleucel (Liso-Cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) After Two or More Prior Lines of Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S388.	0.2	1
38	Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 4149-4155.	2.5	42
39	Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 768.e1-768.e6.	0.6	4
40	Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3034-3043.	0.8	76
41	Belumosudil: A Rising Star for the Management of Chronic Graft-Versus-Host Disease and the First FDA-Approved ROCK2 Inhibitor. , 2021, 18, .		0
42	4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. , 2021, 9, e003354.		32
43	Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma. <i>JAMA Oncology</i> , 2020, 6, 281.	3.4	36
44	Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4898-4911.	2.5	238
45	Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. <i>Clinical Cancer Research</i> , 2020, 26, 4823-4831.	3.2	47
46	Chimeric Antigen Receptor T Cell Therapy Delivers Response in Lymphoma Progressing after Allogeneic Transplantation, but is the Sequence Optimal?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e211-e212.	2.0	0
47	High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 3268-3276.	2.5	134
48	Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4086-4090.	2.5	22
49	Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 5414-5424.	2.5	263
50	Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. <i>Journal of Clinical Oncology</i> , 2020, 38, 3119-3128.	0.8	481
51	Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1581-1588.	2.0	40
52	KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2020, 382, 1331-1342.	13.9	1,067
53	Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. <i>Blood Advances</i> , 2020, 4, 1432-1439.	2.5	54
54	Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial. <i>Blood Advances</i> , 2020, 4, 1440-1447.	2.5	29

#	ARTICLE	IF	CITATIONS
55	Response to Letter to Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma" Biology of Blood and Marrow Transplantation, 2020, 26, e335-e336.	2.0	4
56	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. , 2020, 8, e001511.		138
57	Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood, 2020, 135, 2106-2109.	0.6	90
58	Ruxolitinib: A Long-Awaited Standard for Steroid Refractory Acute Graft-Versus-Host Disease. , 2020, 17, .		0
59	Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy. British Journal of Haematology, 2019, 187, e35-e38.	1.2	35
60	Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1012-1021.	0.4	105
61	Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells. American Journal of Hematology, 2019, 94, E245-E247.	2.0	1
62	Beat pediatric ALL MRD: CD28 CAR T and transplant. Blood, 2019, 134, 2333-2335.	0.6	5
63	Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). Journal of the American College of Cardiology, 2019, 74, 3099-3108.	1.2	225
64	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2019, 25, 683-688.	2.0	18
65	ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biology of Blood and Marrow Transplantation, 2019, 25, 625-638.	2.0	1,741
66	Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities. BioDrugs, 2019, 33, 45-60.	2.2	61
67	Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase "2 trial. Lancet Oncology, The, 2019, 20, 31-42.	5.1	1,467
68	CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel. Blood, 2019, 134, 203-203.	0.6	48
69	CAR T cell therapy for B-cell lymphomas. Best Practice and Research in Clinical Haematology, 2018, 31, 135-146.	0.7	39
70	Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nature Reviews Clinical Oncology, 2018, 15, 218-218.	12.5	114
71	CAR T-Cell Therapy in Large B-Cell Lymphoma. New England Journal of Medicine, 2018, 378, 1065-1065.	13.9	53
72	Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study. Biology of Blood and Marrow Transplantation, 2018, 24, 400-405.	2.0	5

#	ARTICLE	IF	CITATIONS
73	Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e35-e39.	0.2	18
74	Chimeric antigen receptor T-cell therapy " assessment and management of toxicities. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 47-62.	12.5	1,659
75	<i>In vivo</i> IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2018, 103, 531-539.	1.7	25
76	Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 2887.	2.2	19
77	Patient-Reported and Neurocognitive Outcomes in Patients Treated with Axicabtagene Ciloleucel. <i>Blood</i> , 2018, 132, 2289-2289.	0.6	5
78	Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience. <i>Blood</i> , 2018, 132, 91-91.	0.6	81
79	Long-Term Follow up of Front-Line Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide (HiLO trial) for Treatment-Na ⁺ ve Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 3150-3150.	0.6	0
80	Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. <i>Molecular Therapy</i> , 2017, 25, 285-295.	3.7	498
81	IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2017, 102, 948-957.	1.7	33
82	Regulatory challenges and considerations for the clinical application of CAR-T cell anti-cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 659-661.	1.4	14
83	CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 405-411.	2.0	11
84	A Possible Cure for Refractory DLBCL: CARs Are Headed in the Right Direction. <i>Molecular Therapy</i> , 2017, 25, 2241-2243.	3.7	2
85	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 2531-2544.	13.9	3,865
86	Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap. , 2017, 5, 59.		5
87	Abstract CT019: Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL). <i>Cancer Research</i> , 2017, 77, CT019-CT019.	0.4	17
88	Abstract CT020: Immune signatures of cytokine release syndrome and neurologic events in a multicenter registrational trial (ZUMA-1) in subjects with refractory diffuse large B cell lymphoma treated with axicabtagene ciloleucel (KTE-C19). , 2017, , .		5
89	Cutting Edge: Engineering Active IKK ² in T Cells Drives Tumor Rejection. <i>Journal of Immunology</i> , 2016, 196, 2933-2938.	0.4	18
90	A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1. <i>Blood</i> , 2016, 128, 998-998.	0.6	26

#	ARTICLE	IF	CITATIONS
91	Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease. <i>Haematologica</i> , 2015, 100, 970-977.	1.7	19
92	Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma. , 2015, 3, 20.		8
93	Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft-versus-Host Disease: Phase I Trial Results. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1074-1082.	2.0	14
94	Myeloablative Intravenous Pharmacokinetically Targeted Busulfan Plus Fludarabine As Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 335-340.	0.2	8
95	Merkel Cell Carcinoma and Immunosuppression: What We Still Need to Know. <i>Journal of the National Cancer Institute</i> , 2015, 107, dju422-dju422.	3.0	15
96	Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2015, 126, 3991-3991.	0.6	9
97	Sequential Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide Is a Safe and Effective Regimen for the Treatment of Previously Treated and Untreated CLL/SLL: The Hilo Trial. <i>Blood</i> , 2015, 126, 2941-2941.	0.6	0
98	Impact of Splenomegaly in the Presence of Negative PET FDG Avidity on Allogeneic Hematopoietic Cell Transplant Outcomes in Patients with Lymphoid Malignancies. <i>Blood</i> , 2015, 126, 5524-5524.	0.6	0
99	Hypo-Albuminemia at Day+90 after Allogeneic Hematopoietic Cell Transplantation for Lymphoid Malignancies Independently Predicts for Inferior Overall Survival and Higher Non-Relapse Mortality. <i>Blood</i> , 2015, 126, 4407-4407.	0.6	0
100	Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2015, 126, 2730-2730.	0.6	2
101	Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2014, 38, 1165-1172.	0.4	14
102	Immunotherapy strategies for multiple myeloma: the present and the future. <i>Immunotherapy</i> , 2013, 5, 1005-1020.	1.0	4
103	Phase II Study of CD4+-Guided Pentostatin Lymphodepletion and Pharmacokinetically Targeted Busulfan as Conditioning for Hematopoietic Cell Allografting. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1087-1093.	2.0	12
104	Conditional Deletion of PTEN in Peripheral T Cells Augments TCR-Mediated Activation but Does Not Abrogate CD28 Dependency or Prevent Energy Induction. <i>Journal of Immunology</i> , 2013, 191, 1677-1685.	0.4	12
105	A Phase I/II Trial Evaluating The Use Of a Histone Deacetylase Inhibitor Panobinostat (LBH589) In Addition To Glucocorticoids In Patients With Acute Graft-Versus-Host Disease. <i>Blood</i> , 2013, 122, 3308-3308.	0.6	3
106	Evaluation Of Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Of One Hundred Thirty-Two Patients With Myelodysplastic Syndrome (MDS) Or Chronic Myelomonocytic Leukemia (CMML) Up To Age Seventy-Five and The Effect Of Pre-Transplant 5-Azacitidine. <i>Blood</i> , 2013, 122, 2152-2152.	0.6	0
107	A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2012, 97, 1882-1889.	1.7	82
108	What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 350-353.	0.9	4

#	ARTICLE	IF	CITATIONS
109	The Anti-CD25 Antibody Daclizumab Delays Treg Reconstitution, Promotes CD4 Memory, and Does Not Prevent Acute or Chronic Gvhd After Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 4195-4195.	0.6	1
110	Gene Deletions of 17p or 11q Are Independent Predictors of Decreased Progression-Free Survival and Overall Survival Following Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 2007-2007.	0.6	0
111	Survival Advantage of Cell Therapy Over Cytotoxic Therapy Alone in Adult Patients with Relapsed AML After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 1994-1994.	0.6	0
112	What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 350-3.	0.9	4
113	Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd. <i>Blood</i> , 2011, 118, 323-323.	0.6	1
114	Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PBA±R) Using a Novel Principle of CD4-Guided Immune Suppression. <i>Blood</i> , 2011, 118, 3022-3022.	0.6	0
115	A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes. <i>Blood</i> , 2011, 118, 496-496.	0.6	0
116	A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 509-514.	1.1	16